AnalyzeDirect Meijer E, Drenth JP, d’Agnolo H, Casteleijn NF, de Fijter JW, Gevers TJ, Kappert P, Peters DJ, Salih M, Soonawala D, Spithoven EM, Torres VE, Visser FW, Wetzels JF, Zietse R, Gansevoort RT. Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to halt disease progression in autosomal dominant polycystic kidney disease. Am J Kidney Dis. March 2014;63(3):446-455.
Full Text – Open Access
Publication Date
March 2014
How Analyze was Used
“The MRI acquisition protocol includes T2-weighted single-shot fast gradient spin-echo images with fat-saturation. MR images will be sent to the central reading facility, using a secure server. MRI end point data will be analyzed and read centrally using Analyze 11 software (AnalyzeDirect Inc) to assess total kidney volume with a stereology method.”
Keywords
Adolescent
Adult
Antineoplastic Agents/administration & dosage/therapeutic use
Cyst progression
Disease Progression
Disease Trajectory
Dose-Response Relationship, Drug
Female
Follow-Up Studies
Glomerular Filtration Rate/drug effects
Glomerular Filtration Rate (GFR)
Humans
Injections, Subcutaneous
Kidney Volume
Male
Middle Aged
Peptides, Cyclic/administration & dosage/therapeutic use
Polycystic Kidney, Autosomal Dominant/drug therapy/physiopathology
Polycystic Kidney Disease (PKD)
Quality of Life
Renal Disease
Somatostatin/administration & dosage/analogs & derivatives/therapeutic use
Somatostatin Analog
Treatment Outcome
Young Adult
Author Affiliation(s)
Department of Nephrology, University Medical Center Groningen, University Hospital Groningen, Groningen, the Netherlands. (EM, NFC, EMS, FWV, RTG)
Department of Gastroenterology and Hepatology, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands. (JPHD, HdA, TJG)
Department of Nephrology, Leiden University Medical Center, Leiden, the Netherlands. (JWdF)
Department of Radiology, University Medical Center Groningen, Groningen, the Netherlands. (PK)
Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands. (DJMP, DS)
Department of Nephrology, Erasmus Medical Center Rotterdam, Rotterdam, the Netherlands. (MS, RZ)
Department of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, US. (VET)
Department of Nephrology, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands. (JFMW)
ID# 50
Tags: Adolescent, Adult, Antineoplastic Agents/administration & dosage/therapeutic use, Autosomal Dominant Polycystic Kidney /drug therapy/physiopathology, Cyclic Peptides/administration & dosage/therapeutic use, Cyst progression, Disease Progression, Disease Trajectory, Drug Dose-Response Relationship, Female, Follow-Up Studies, Glomerular Filtration Rate (GFR), Glomerular Filtration Rate/drug effects, Humans, Kidney Volume, Male, Middle Aged, Polycystic Kidney Disease (PKD), Quality of Life, Renal Disease, Somatostatin Analog, Somatostatin/administration & dosage/analogs & derivatives/therapeutic use, Subcutaneous Injections, Treatment Outcome, Young Adult